Full Press Release Details
Receives Notification of Patent Grant from European Patent Office
for Namodenoson in the Treatment of NASH
TIKVA, Israel, August 25, 2020 -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing
a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the
European Patent Office has notified the Company of its intent to grant a patent for the invention titled "An A3 Adenosine
Receptor For Use In Treating Ectopic Fat Acculturation". Patent claims include use of the A3 adenosine receptor (A3AR),
the target of Can-Fite's platform technology, in reducing ectopic fat accumulation particularly in fatty liver as manifested
in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
important patent in Europe comes as Namodenoson exhibited a strong safety profile and met its efficacy endpoints in the treatment
of NAFLD and NASH in our recently completed Phase II study. Our global IP portfolio addressing NAFLD/NASH is critical as we engage
in talks with potential distribution partners," stated Can-Fite CEO Dr. Pnina Fishman. "NAFLD and NASH have a very
heavy disease burden in Europe, where epidemiology studies estimate the prevalence among the general population of NAFLD at between
29-37%, with 16-45% of those biopsy confirmed as NASH."
has received patents for Namodenoson in the treatment of NAFLD/NASH in the U.S. and Korea, and the Company has licensing and distribution
agreements for Namodenoson in this indication in China and Korea. There is currently no U.S. FDA approved drug for the treatment
of NASH, which is an addressable pharmaceutical market estimated to reach $35-40 billion by 2025.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19.
The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's
liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer,
and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH).
Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment
for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers
including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile
dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
For more information please visit: www.can-fite.com.
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations,
strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking
statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe,"
"expect," "intend," "plan," "may," "should" or "anticipate"
or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate
strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various
filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the
approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual
results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could
cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking
statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and
our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working
capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate
development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical
studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory
filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability
to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model
and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual
property rights of others; competitive companies, technologies and our industry; statements as to the impact of the political
and security situation in Israel on our business; and risks and other risk factors detailed in Can-Fite's filings with the
SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector where securities values are
highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does not undertake any obligation
to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.